Flexsteel Industries Inc

Stock futures edged lower on Tuesday as investors weighed a fresh surge in crude oil prices driven by stalled diplomatic talks and lingering concerns over a prolonged blockade of the Strait of Hormuz. Amylyx Pharmaceuticals climbed 44% after its Phase 3 LUCIDITY trial of avexitide met its primary and all secondary endpoints, with the once-daily injectable reducing Level 2 and Level 3 hypoglycemic events by 55% versus placebo over 16 weeks. Duos Technologies Group rose 21% after reporting upbeat Q2 results and reaffirming its 2026 targets of 25 MW deployed and more than $50M in revenue, while Flexsteel Industries gained 11% after beating FQ4 earnings and revenue estimates and providing above-consensus Q1 sales guidance. Klarna fell 21% after issuing weaker-than-expected Q3 and full-year guidance, citing lower German volumes, FX headwinds, and changes to fair financing accounting, while Fabrinet dropped 18% despite a strong FQ4 beat and above-consensus Q1 guidance. Kulicke & Soffa slid 10% after naming Raj Talluri as President and CEO, and Baidu fell 9% after Q2 revenue and adjusted EPS missed estimates, with online marketing revenue declining 19% and total revenue falling 4% year-over-year to RMB31.3B.

Flexsteel Industries reported fourth quarter 2026 results with revenue growth of 27.3%, driven by a structural shift in customer demand toward AI-driven drug discovery and high-throughput protein expression. Management attributed record adjusted net profit growth of over 200% to improved business quality and operating leverage from long-term investments in automation and digital capacity. The Life Science Group achieved a 29.5% adjusted operating margin, marking a transition from an investment phase to a scale-and-profitability phase. Full-year revenue growth guidance for the Life Science segment was raised to 25%-30%, reflecting strong visibility into AIDD-related order momentum. AIDD orders are projected to double in the second half of 2026, with management expecting this hyper-growth trajectory to compound over the next several years. The company expects to achieve positive EBITDA for the ProBio CDMO segment by 2027, supported by a 54% year-over-year increase in new orders. CapEx for 2026 is projected at approximately USD 130 million, focused on doubling throughput capacity every quarter to meet surging AI-driven validation demand. Management assumes that the premium margins for AIDD services, roughly 20 points higher than traditional protein orders, will remain sustainable due to the high value of model-ready data. Prior period figures were adjusted to exclude the financial impact of the Renova license transaction to provide a more objective view of underlying performance. Management identified the primary industry bottleneck as the validation of AI-generated designs, which traditional experimental workflows are not equipped to handle at scale. The company maintains a robust cash position of approximately USD 830 million, stating there is no immediate need for incremental financing despite aggressive capacity expansion. Tariff refunds in the U.S. impacted gross margins, with adjusted figures provided to show the underlying operational improvement excluding these one-time effects. In the Q&A session, management noted that AIDD programs require exponentially higher throughput and continuous engagement compared to traditional discovery, and current guidance is described as prudent with potential for further upside if the trend of complex, recurring AIDD projects continues to accelerate. Management claims a clear advantage in speed and data quality, delivering binding data in 4 to 7 days compared to an industry average of over 2 weeks, and GenScript captures more than twice the revenue per delivered item versus its primary competitor by focusing on end-to-end validation rather than just DNA fragments. The company's modular workstation infrastructure allows for faster capacity expansion with lower capital intensity than large-format systems. New AI-native and tech-sector customers require validation for thousands of candidate sequences in a single iteration, necessitating a shift from months to days in feedback loops, and the deliverable for these clients is not just a biological construct but high-quality experimental data used to retrain and improve AI models. This segment is viewed as a structural long-term driver because it embeds GenScript into the customer's core R&D digital infrastructure.

Zacks.com featured Dycom Industries, Cimpress, The Marcus Corp., and Flexsteel Industries as stocks with rising cash flows worth buying. The screen identifies companies with increasing net cash flow, which signals management efficiency and reduced reliance on outside financing. Dycom Industries saw its fiscal 2027 earnings estimate rise 2.6% over 30 days to $16.35 per share. Cimpress had its fiscal 2026 estimate improve 5.2% over 60 days to $3.81 per share. The Marcus Corp.'s 2026 earnings estimate moved up 8.2% over seven days to 53 cents per share, while Flexsteel Industries' fiscal 2026 estimate was revised upward 2.8% over 60 days to $4.78 per share.

Zacks Investment Research highlights Liquidia Corporation, Flexsteel Industries, and Argan as low-beta stocks worth buying amid persistent market uncertainty. The screen selected stocks with a beta between 0 and 0.6, a positive four-week price change, average 20-day volume above 50,000, a price of at least $5, and a Zacks Rank of 1, or Strong Buy. Liquidia is seeing rapid adoption of its YUTREPIA treatment, has achieved profitability, and is generating positive cash flow. Flexsteel Industries, a furniture manufacturer, benefits from a debt-free balance sheet and strong cash position. Argan holds a $2.8 billion backlog and no debt, positioning it to meet rising demand for power infrastructure.